

Page 1 of 2

K061344 (Pg 1 of 2)

B. 510(k) SUMMARY (as required by 21 CFR 807.92)

**Excia Total Hip System
(Excia Lateral Offset)**
May 12, 2006

AUG 02 2006

COMPANY: Aesculap[®], Inc.
3773 Corporate Parkway
Center Valley, PA 18034
Establishment Registration Number: 2916714

CONTACT: Kathy A. Racosky
800-258-1946 (phone)
610-791-6882 (fax)
kathy.racosky@aesculap.com (email)

TRADE NAME: Excia Total Hip System Lateral Offset

COMMON NAME: Femoral Hip Stem

CLASSIFICATION NAME: Prosthesis, hip, semi-constrained, metal/polymer, uncemented
Prosthesis, hip, semi-constrained, metal/polymer, cemented
Prosthesis, Hip, semi-constrained, uncemented, metal/polymer, non-porous, calcium-phosphate
Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented or Non-Porous, Uncemented

REGULATION NUMBER: 888.3360, 888.3350, 888.3353, 888.3353

PRODUCT CODE: LWJ, JDI, MEH, LZO

SUBSTANTIAL EQUIVALENCE

Aesculap[®], Inc. believes that the Lateral Offset Femoral Stem is a line extension of Aesculap's Excia Total Hip System that was cleared (K042344). It is also substantially equivalent to the Excia Total Hip System with μ -CaP[®] (K060437), BiContact Hip System (K040191), PERFECTA RS Lateralized Hip Stem (K991123) and Dual Offset PERFECTA IMC Hip Stem (K972641):

DEVICE DESCRIPTION

The Excia lateral offset femoral stem is available in two designs and standard lengths. The stem is designed to provide an increased offset during total joint replacement. One is manufactured from Ti with a plasma spray coating (Plasmapore) with or without μ -CaP[®]. This component is intended for uncemented use. The other femoral component is manufactured from CoCrMo and is intended for cemented use.

Page 2 of 2

INDICATIONS FOR USE

The Excia Hip System is intended to replace a hip joint.

The device is intended for:

- Patients suffering from severe hip and disability due to rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head and nonunion of previous fractures of the femur.
- Patients with congenital hip dysplasia, protrusion acetabuli, or slipped capital femoral epiphysis
- Patients suffering from disability due previous fusion
- Patients with acute femoral neck fractures

The Excia Hip System is available with two femoral stems. One is manufactured from CoCrMo and is intended for cemented fixation. The other femoral stem is for uncemented fixation and manufactured from Ti with Plasmapore with or without μ CaP®.

TECHNOLOGICAL CHARACTERISTICS(compared to Predicate(s))

The new lateral offset femoral stems of the Excia Total Hip System are offered in similar shapes and sizes as the predicate devices. The material used for the Aesculap device is the same as that used to manufacture the predicate devices.

PERFORMANCE DATA

All required testing per "Draft Guidance for the Preparation of Premarket Notifications (510(k)s) Applications for Orthopedic Devices-The Basic Elements" were done where applicable. In addition, testing per the;

- "Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement",
- "Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements",
- "Guidance Document for Testing Non-articulating, "Mechanically Locked" Modular Implant Components",
- "Draft Guidance Document for Testing Acetabular Cup Prostheses",
- "Points to Consider for Femoral Stem Prostheses",
- "Guidance Document for the Preparation of Premarket Notifications for Ceramic Ball Hip Systems and
- "Data Requirements for Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices" was completed where applicable.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 02 2006

Ms. Kathy A. Racosky
Regulatory Affairs Associate
Aesculap, Inc.
3773 Corporate Parkway
Center Valley, Pennsylvania 18034

Re: K061344

Trade/Device Name: Excia Total Hip System Lateral Offset
Regulation Number: 21 CFR 888.3353
Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous
uncemented prosthesis
Regulatory Class: Class II
Product Code: LZO, JDI, LWJ, MEH
Dated: July 20, 2006
Received: July 21, 2006

Dear Ms. Racosky:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Ms. Kathy A. Racosky

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Page 1 of 1

A. INDICATIONS FOR USE STATEMENT510(k) Number: K061344

Device Name: Excia Lateral Offset


Indications for Use:

The Excia Hip System is intended to replace a hip joint.

The device is intended for:

- Patients suffering from severe hip and disability due to rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head and nonunion of previous fractures of the femur
- Patients with congenital hip dysplasia, protrusion acetabuli, or slipped capital femoral epiphysis
- Patients suffering from disability due to previous fusion
- Patients with acute femoral neck fractures

The Excia Hip System is available with two femoral stems. One is manufactured from CoCrMo and is intended for cemented fixation. The other femoral stem is for uncemented fixation and manufactured from Ti with Plasmapore with or without μ CaP®.

**(Division Sign-Off)****Division of General, Restorative,
and Neurological Devices**510(k) Number K061344Prescription Use X and/or Over-the-Counter Use _____

(per 21 CFR 801.109)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)